Filtered By:
Specialty: Drugs & Pharmacology
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 124567 results found since Jan 2013.
Simplification and Multidimensional Adaptation of the Stratification Tool for Pharmaceutical Care in People Living With HIV
CONCLUSIONS AND RELEVANCE: We created a new pyramid of score thresholds to classify patients into priority levels. The new tool simplifies the 2017 model and improves its utility to help HIV-positive patients, owing to its multidimensional approach.PMID:35707861 | DOI:10.1177/10600280221096759
Source: The Annals of Pharmacotherapy - June 16, 2022 Category: Drugs & Pharmacology Authors: Ram ón Morillo-Verdugo Tamara Aguilar P érez Mercedes Gimeno-Gracia Carmen Rodr íguez-González Mar ía de Las Aguas Robustillo-Cortes representing the project research team belonging to the HIV Pharmaceutical Care group of the < italic toggle="yes" > Source Type: research
Emtricitabine/Tenofovir Alafenamide (Descovy) for HIV
Date: August 1, 2016
Issue #:
1500 Summary:
The FDA has approved Descovy (Gilead), a fixed-dose
combination of the nucleoside/nucleotide reverse
transcriptase inhibitors (NRTIs) emtricitabine (FTC)
and tenofovir alafenamide (TAF) for use with other
antiretroviral agents for treatment of HIV-1 infection. A
combination of emtricitabine and tenofovir disoproxil
fumarate (FTC/TDF; Truvada) has been available
since 2004 for the same indication. Emtricitabine
and TAF are also available in combination with the
non-nucleoside reverse transcriptase inhibitor
(NNRTI) rilp...
Source: The Medical Letter - July 26, 2016 Category: Drugs & Pharmacology Authors: admin Tags: cobicistat Descovy elvitegravir Emtricitabine emtricitiabine/tenofovir Genvoya HIV Odefsey rilpivirine tenofovir alafenamide Truvada Source Type: research
Few HIV Patients Treated for Hep C Given Contraindicated HIV Drugs Few HIV Patients Treated for Hep C Given Contraindicated HIV Drugs
Few people who are co-infected with HCV and HIV and are being treated with direct-acting antivirals also receive contraindicated antiretrovirals, European researchers report.Medscape Medical News
Source: Medscape Pharmacist Headlines - August 22, 2022 Category: Drugs & Pharmacology Tags: HIV/AIDS News Source Type: news
Using Drugs to Prevent HIV Infection: Who, What, and When?Using Drugs to Prevent HIV Infection: Who, What, and When?
Dr. Myron Cohen considers some of the key challenges facing clinicians in determining which patients might benefit from preexposure prophylaxis for HIV infection. Medscape HIV/AIDS
Source: Medscape Pharmacist Headlines - May 22, 2014 Category: Drugs & Pharmacology Tags: HIV/AIDS Expert Interview Source Type: news
The Challenges of Implementing HIV Preexposure ProphylaxisThe Challenges of Implementing HIV Preexposure Prophylaxis
Dr. Paul Sax considers the challenges facing physicians charged with implementing the CDC's recent guidelines on HIV pre-exposure prophylaxis. Medscape HIV/AIDS
Source: Medscape Pharmacist Headlines - June 18, 2014 Category: Drugs & Pharmacology Tags: HIV/AIDS Commentary Source Type: news
FDA Expands Indications for Pifeltro and Delstrigo for HIV FDA Expands Indications for Pifeltro and Delstrigo for HIV
The FDA expanded the indications for the two HIV drugs to include appropriate patients with HIV-1 with virological suppression.FDA Approvals
Source: Medscape Pharmacist Headlines - September 20, 2019 Category: Drugs & Pharmacology Tags: HIV/AIDS News Alert Source Type: news
CDC Updates HIV Preexposure Prophylaxis GuidelinesCDC Updates HIV Preexposure Prophylaxis Guidelines
The CDC has outlined 4 groups that should receive PrEP and emphasizes the importance of adherence to medication and routine HIV testing. Medscape Medical News
Source: Medscape Pharmacist Headlines - May 15, 2014 Category: Drugs & Pharmacology Tags: HIV/AIDS News Source Type: news
Progress and challenges in the use of latent HIV-1 reactivating agents
; Fu-jun Liang
Source: Acta Pharmacologica Sinica - August 4, 2015 Category: Drugs & Pharmacology Authors: Hong-tao ShangJi-wei DingShu-ying YuTao WuQiu-li ZhangFu-jun Liang Tags: HIV infection virus latency HIV reactivating agents interleukin-7 disulfram protein kinase C agonist histone deacetylase inhibitors DNA methyltranserase inhibitors “shock and kill” strategy CD4-positive T-lymphocytes Source Type: research
Truvada Recommended as First Drug for HIV PrEP in Europe Truvada Recommended as First Drug for HIV PrEP in Europe
Although not a new drug, it is the first drug for HIV preexposure prophylaxis to be recommended for approval in the European Union. International Approvals
Source: Medscape Pharmacist Headlines - July 22, 2016 Category: Drugs & Pharmacology Tags: HIV/AIDS News Alert Source Type: news
HIV Drug Raltegravir Approved for Neonates HIV Drug Raltegravir Approved for Neonates
Raltegravir is the only integrase inhibitor approved in the US for treatment of HIV in newborns from birth to 4 weeks of age weighing at least 2 kg.FDA Approvals
Source: Medscape Pharmacist Headlines - December 12, 2017 Category: Drugs & Pharmacology Tags: HIV/AIDS News Alert Source Type: news
EU Panel Backs Dolutegravir/Lamivudine Combo Pill for HIV EU Panel Backs Dolutegravir/Lamivudine Combo Pill for HIV
Dovato contains 50 mg dolutegravir and 300 mg lamivudine and would be the first once-daily, single-pill, completed 2-drug regimen for treatment of HIV in Europe.International Approvals
Source: Medscape Pharmacist Headlines - April 26, 2019 Category: Drugs & Pharmacology Tags: HIV/AIDS News Alert Source Type: news
FDA OKs First-in-Class HIV Therapy for Patients With Few Options FDA OKs First-in-Class HIV Therapy for Patients With Few Options
Fostemsavir (Rukobia) is indicated for heavily treatment-experienced patients living with multidrug-resistant HIV infection.FDA Approvals
Source: Medscape Pharmacist Headlines - July 7, 2020 Category: Drugs & Pharmacology Tags: HIV/AIDS News Alert Source Type: news
Many Health Plans Must Cover Full Cost of HIV Prevention Drugs Many Health Plans Must Cover Full Cost of HIV Prevention Drugs
Starting this month, most people with private insurance will no longer have to decide whether they can afford to protect themselves against HIV.Kaiser Health News
Source: Medscape Pharmacist Headlines - January 6, 2021 Category: Drugs & Pharmacology Tags: HIV/AIDS News Source Type: news
FDA OKs First Injectable Complete Drug Regimen for HIV FDA OKs First Injectable Complete Drug Regimen for HIV
Cabenuva is a once-monthly injectable formulation of cabotegravir and rilpivirine for adults with HIV-1 infection whose condition is currently stable with an antiretroviral regimen.FDA Approvals
Source: Medscape Pharmacist Headlines - January 28, 2021 Category: Drugs & Pharmacology Tags: HIV/AIDS News Alert Source Type: news
Nearly Half of HIV PrEP Descovy Switches Contraindicated Nearly Half of HIV PrEP Descovy Switches Contraindicated
For nearly 2 years, a newer and more expensive version of the first HIV prevention pill has been available to people who can benefit. Should you prescribe it?Medscape Medical News
Source: Medscape Pharmacist Headlines - September 22, 2021 Category: Drugs & Pharmacology Tags: HIV/AIDS News Source Type: news
